Congratulations to Luisa Chocarro - the latest winner of our $500 Early Career Scientist Grant! 🎉 Luisa Chocarro de Erauso told us how the grant will fund her trip to #ESMO2024: ow.ly/ljvm50T492c #sciencefunding #sciencegrant #PhDsupport #PhDforum #academictwitter

🧐¿Sabes lo que es la #medicinapersonalizada?🧐 Es un enfoque innovador que permite adaptar el tratamiento a las características individuales de cada persona. Apúntate a la jornada de este viernes para saber más: forms.office.com/pages/response… #TodosContraElCáncer

📢 Este viernes no te pierdas la jornada informativa sobre los avances en #MedicinaPersonalizada y Terapias Avanzadas en #Navarra 👥 Organiza: Gobierno de Navarra 🗓️ 30/08 🕙10h 📍Salón de actos Navarrabiomed Inscripción previa 👉 forms.office.com/pages/response… Programa completo ⬇️

El Hospital Universitario de Navarra recibe una acreditación internacional que reconoce su excelencia en el tratamiento del cáncer ➡️Se trata de la certificación QOPI, entregada por la fundación ECO y la Sociedad Americana de Oncología Salud - Osasuna 🔗navarra.es/es/-/nota-pren…

La investigación en cáncer se traduce en más vida. Impulsemos la investigación para superar el 70% de supervivencia en cáncer en 2030

📣 Investigadores del Cima y de la Clínica Universidad de Navarra han demostrado que un nuevo tratamiento combinado de radioterapia e inmunoterapia mejora la supervivencia en modelos preclínicos de tumores cerebrales pediátricos. cima.cun.es/actualidad/not…

Tumor dynamics in patients treated with anti-PD-1 monotherapy beyond progression (TBP) 👉 cell.com/cancer-cell/fu… (Cancer Cell) 🗝 Key findings: #Melanoma: ORR 8.6% #NSCLC: ORR 2.8% #GastricCancer: ORR 3.4% #HNSCC: ORR 3.6% #RCC: ORR 7.8% Urothelial Carcinoma: ORR 6.2%

La investigación se traduce en avances contra el cáncer 👇 La combinación de dos fármacos mejora en animales el tratamiento del cáncer cerebral infantil más agresivo. 🔬Dra. Marta Alonso Clínica Universidad de Navarra #WorldCancerResearchDay #TodosContraelCáncer traduciendolainvestigacionencancer.es/dra-marta-alon…

Thrilled to welcome #ESMO2024 after a challenging year! A heartfelt thank you to the global medical oncology community for your unwavering support. Together, we’ll continue to advance the field and serve our global society with dedication and innovation ESMO - Eur. Oncology OncoDaily

#ESMO24 Congress Programme numbers are really breathtaking! The result of a global community’s commitment to fighting cancer #ESMOAmbassadors ESMO - Eur. Oncology

#ESMO24 in numbers, just #impressive -almost 33000 attendees -598 speakers -5030 abstracts submitted -2186 abstracts accepted -83 LBAs -3 plenary sessions -1+4 press conferences -151 proffered papers -207 mini orals -1828 posters ESMO - Eur. Oncology #ESMOAmbassadors

The growth of the annual ESMO Congress is incredible! 📈 #ESMO24

Presented at #ESMO24: Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone. Full CheckMate 067 trial results: nej.md/4dUqm0g

👩‍🔬 .Luisa Chocarro de Erauso predoctoral OncoImmunology researcher in Navarrabiomed 🥇 Best Poster Award in Basic Science by the European Society for Medical #Oncology (#ESMO)📍 Barcelona Congratulations Luisa!!👏👏 #ESMO24 David Escors

#Presidential Symposium III: #Eyes to the #Future at #ESMO24 👁️🔮 (1/2) 1️⃣ROME trial - targeted therapy vs SOC 2️⃣GigaPath - AI to predict genomic alterations 3️⃣4️⃣NO-CUT trial - multiomics and multidisciplinarity in oncology 👉 organ preservation ESMO - Eur. Oncology #ESMOAmbassadors SEOM

🔥Presidential Symposium III: Eyes to the future🔥 Precision immuno-oncology for advanced NSCLC pts with PD-(L)1 inhibitors resistance #ESMO24 🔎PIONeeR phs Ib/IIa clinical trial targeting identified resistance pathways 🧐Innovative trial to overcome resistance to ICI ESMO - Eur. Oncology

#Presidential Symposium III: #Eyes to the #Future at #ESMO24 👁️🔮 (2/2) 1️⃣2️⃣PIONeeR trial - Resistance to iPD(L)1 3️⃣4️⃣MTAP loss - targeting epigenetics (also in #BiliaryCancers and #PDAC 😉) ESMO - Eur. Oncology #ESMOAmbassadors Asociación ATUVIBI AMMF Cholangiocarcinoma Foundation ACanPan